JP2015147774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015147774A5 JP2015147774A5 JP2015047791A JP2015047791A JP2015147774A5 JP 2015147774 A5 JP2015147774 A5 JP 2015147774A5 JP 2015047791 A JP2015047791 A JP 2015047791A JP 2015047791 A JP2015047791 A JP 2015047791A JP 2015147774 A5 JP2015147774 A5 JP 2015147774A5
- Authority
- JP
- Japan
- Prior art keywords
- androstan
- ethynyl
- oxime
- hydroxyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XPZHAZFQUFNMAU-HKQXQEGQSA-N N-[(5R,8R,9S,10S,13S,14S)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-ylidene]hydroxylamine Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=NO)[C@@H]4[C@@H]3CC[C@H]21 XPZHAZFQUFNMAU-HKQXQEGQSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (2)
- 3α−エチニル、3β−ヒドロキシル,アンドロスタン−17−オンオキシム、または薬学的に許容されるその塩。
- 3α−エチニル、3β−ヒドロキシル,アンドロスタン−17−オンオキシムと、薬学的に許容される担体とを含む、医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86065806P | 2006-11-21 | 2006-11-21 | |
US60/860,658 | 2006-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013097486A Division JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015147774A JP2015147774A (ja) | 2015-08-20 |
JP2015147774A5 true JP2015147774A5 (ja) | 2016-03-10 |
Family
ID=39429970
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097487A Active JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097487A Active JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Country Status (16)
Country | Link |
---|---|
US (9) | US8580983B2 (ja) |
EP (4) | EP2711371B1 (ja) |
JP (5) | JP5386362B2 (ja) |
AU (1) | AU2007322423C1 (ja) |
BR (2) | BRPI0718945B8 (ja) |
CA (2) | CA2664126C (ja) |
DK (3) | DK2792681T3 (ja) |
ES (3) | ES2543841T3 (ja) |
HU (3) | HUE033037T2 (ja) |
IN (1) | IN2014DN02014A (ja) |
MX (1) | MX2009005335A (ja) |
PL (3) | PL2097437T3 (ja) |
PT (1) | PT2097437E (ja) |
RU (1) | RU2458065C2 (ja) |
SI (1) | SI2097437T1 (ja) |
WO (1) | WO2008063128A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009005335A (es) | 2006-11-21 | 2009-06-08 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
JP5687287B2 (ja) | 2010-01-14 | 2015-03-18 | ウメクライン ムード エービー | 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物 |
EP2566482A1 (en) * | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
EP2925770B1 (en) * | 2012-11-28 | 2017-01-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone |
JP6255082B2 (ja) | 2013-03-13 | 2017-12-27 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイドおよびその使用方法 |
TR201901687T4 (tr) | 2014-01-29 | 2019-02-21 | Umecrine Cognition Ab | Hepatik ensefalopati tedavisinde kullanıma yönelik steroid bileşik. |
HUE049014T2 (hu) * | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
TWI748936B (zh) * | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
KR20180026742A (ko) | 2015-07-06 | 2018-03-13 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
BR112018070123A2 (pt) | 2016-04-01 | 2019-02-05 | Sage Therapeutics Inc | oxiesterós e métodos de uso dos mesmos |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
KR20230051723A (ko) | 2016-10-18 | 2023-04-18 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
EP3579842A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS |
MX2019008763A (es) | 2017-02-10 | 2019-10-21 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso en tratamiento medico. |
JP7314459B2 (ja) | 2017-11-27 | 2023-07-26 | ウメクリン コグニチオン アーべー | 3α-エチニル-3β-ヒドロキシアンドロスタン-17-オンオキシムの医薬製剤 |
CA3094026A1 (en) | 2018-04-05 | 2019-10-10 | Asarina Pharma Aps | Gaba-a antagonists for treating substance withdrawal disorders |
CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083978A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1463755A (fr) | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
US3152121A (en) * | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
CH491889A (de) * | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
JP4066272B2 (ja) | 1994-02-14 | 2008-03-26 | ユーロ‐セルティック エス. ア. | Gaba受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類 |
ATE198753T1 (de) * | 1994-11-23 | 2001-02-15 | Cocensys Inc | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
UA57706C2 (uk) | 1995-06-06 | 2003-07-15 | Косенсіз, Інк | Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти) |
AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
DE69927960T2 (de) | 1998-03-11 | 2006-07-20 | Torbjörn Backström | Epiallopregnanolon zur behandlung von krankheiten des cns |
AU3467699A (en) | 1998-04-14 | 1999-11-01 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
EP1310258A1 (en) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
WO2006054938A1 (en) * | 2004-11-18 | 2006-05-26 | Umecrine Ab | Gaba-steroid antagonists and their use for the treatment of cns disorders |
MX2009005335A (es) | 2006-11-21 | 2009-06-08 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. |
EP2566482A1 (en) | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en active Application Filing
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
-
2012
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja active Active
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015147774A5 (ja) | ||
JP2013173782A5 (ja) | ||
NL301224I2 (nl) | Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
JP2013173781A5 (ja) | ||
JP2018012698A5 (ja) | ||
HK1255566A1 (zh) | 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用 | |
JP2016196495A5 (ja) | ||
JP2016028092A5 (ja) | ||
NL301260I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
JP2016028081A5 (ja) | ||
JP2016065085A5 (ja) | ||
EP3112364A4 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
JP2017137500A5 (ja) | ||
JP2017508572A5 (ja) | ||
JP2018533683A5 (ja) | ||
ZA201804423B (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
JP2017197541A5 (ja) | ||
PL3421038T3 (pl) | Związek naftyrydyny, kompozycja farmaceutyczna i ich zastosowanie | |
WO2015114308A8 (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
JP2018519528A5 (ja) | ||
JP2016053220A5 (ja) | ||
JP2017528459A5 (ja) | ||
EP3530654A4 (en) | CARBOXYLIC ACID COMPOUND WITH QUINOLINYL SUBSTITUTE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
JP2017077228A5 (ja) | 移動式搾乳装置および該移動式搾乳装置を使用した放牧方法 | |
JP2019518052A5 (ja) |